Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial -

Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial
Information type: Randomised controlled trials
Source: JAMA Psychiatry
Specialities: Mental health and illness | Nutritional and metabolic disorders
Summary
RCT (n= 255 with binge-eating [BE] disorder) found at week 11, 50- and 70-mg/d lisdexamfetamine groups showed efficacy vs. placebo group in decreased BE days, BE cessation, and global improvement. Safety profile was generally consistent with previous findings in adults with ADHD.
UKMi comment
In the UK, lisdexamfetamine dimesylate is currently licensed as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder in children aged 6 years and over when response to previous methylphenidate treatment is considered clinically inadequate.
Related links: